Prognostic and Predictive Factors in Patients With Chronic Lymphocytic Leukemia: Relevant in the Era of Novel Treatment Approaches?
Menée à partir de données portant sur 2 972 patients atteints d'une leucémie lymphocytaire chronique, cette étude multicentrique met en évidence une forte association entre l'expression du marqueur CD49d à la surface des cellules néoplasiques, mesurée par cytométrie en flux, et la survie sans traitement ou la survie globale des patients
In modern oncology, we are experiencing a paradigm shift toward personalized medicine. Conceptually, this means that patients will be treated with compounds that specifically target the tumor on the basis of its individual molecular characteristics. Personalized targeted therapy requires the identification of (bio)markers for at least two reasons: first, patients will need to be stratified according to their potential to respond to targeted therapy, and second, response to therapy will need to be assessed by analyzing the molecular target of the therapy. At present, arguably the most direct and frequently used biomarkers are the underlying genetic aberrations of a tumor. In chronic lymphocytic leukemi (CLL), genetic markers are wellknown for their pathogenic and prognostic relevance...
Journal of Clinical Oncology , éditorial en libre accès, 2014